Accepted Articles
Back to the articles list |
Back to browse issues page
Maryam Salehbayat1, Roya Abolfazli2, Niayesh Mohebbi *3, Seyed Mehrdad Savar4, Gloria Shalviri5, Kheirollah Gholami6
1- International Campus, Tehran University of Medical Sciences, Tehran, Iran.
2- Iranian Center of Neurological Research, Tehran University of Medical Sciences, Tehran, Iran.
3- Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences,Tehran, Iran.
4- Research center for rational use of drugs, Tehran University of Medical Sciences, Tehran, Iran.
5- Tehran University of Medical Sciences, Tehran, Iran.
6- Pharmacoepidemiology and Pharmacovigilance Center, Food and Drug Administration, Ministry of Health, Tehran, Iran.
2- Iranian Center of Neurological Research, Tehran University of Medical Sciences, Tehran, Iran.
3- Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences,Tehran, Iran.
4- Research center for rational use of drugs, Tehran University of Medical Sciences, Tehran, Iran.
5- Tehran University of Medical Sciences, Tehran, Iran.
6- Pharmacoepidemiology and Pharmacovigilance Center, Food and Drug Administration, Ministry of Health, Tehran, Iran.
Abstract:
Introduction: High frequency of adverse drug reactions (ADRs) challenges multiple sclerosis (MS) treatment. We aimed to assess the nature and frequency of ADRs induced by MS medications in an observational cross-sectional study.
Material and Methods: ADRs of all outpatients who had been visiting a neurologist and had been receiving at least one disease-modifying therapy (DMT) for MS during the last three months were investigated.
Results: A total number of 484 ADRs were detected in these patients. The preventability rate was 5.9%, and 0.61% of reactions were serious.
Discussion: The high frequency of adverse drug reactions in this study shows a strong need for planning a strategy to increase patients' adherence to treatment.
Material and Methods: ADRs of all outpatients who had been visiting a neurologist and had been receiving at least one disease-modifying therapy (DMT) for MS during the last three months were investigated.
Results: A total number of 484 ADRs were detected in these patients. The preventability rate was 5.9%, and 0.61% of reactions were serious.
Discussion: The high frequency of adverse drug reactions in this study shows a strong need for planning a strategy to increase patients' adherence to treatment.
Type of Study: Commentary |
Subject:
Clinical Neuroscience
Received: 2021/06/23 | Accepted: 2021/08/28
Received: 2021/06/23 | Accepted: 2021/08/28
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Contact Information
Basic and Clinical Neuroscience Journal (BCN)
Iran University of Medical Sciences, Shahid Hemmat Highway, Tehran, Iran.
Publisher Tel:
+9821 453 55 555; +9821 453 55 000 (EXT: 104)
URL: http://bcn.iums.ac.ir/
Publisher Email: info
nirp.ir
